The Top Line · Fierce Life Sciences
From approval to value: Why evidence storytelling now matters (Sponsored)
·18 min·1 clip
Kate Liltzman reveals why payers now demand evidence of long-term value and real-world performance, not just approval.
As heard by us
A practical look at how pharma evidence gets tailored for different audiences.
The episode lands on a familiar but useful point: approval is not the finish line, and evidence still has to do the work with payers and other decision makers. Its best moments are concrete.
Why you'd press play
If you work where evidence has to persuade, this gives you the language for making the value story land.
Listen to the show on